Welcome to our dedicated page for Entera Bio SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. reported a net loss of $3.5M, or $0.07 per share, for the quarter ended March 31, 2026, compared with a $2.6M loss, or $0.06 per share, a year earlier. R&D expenses increased to $2.3M while G&A held roughly flat at $1.3M.
Cash and cash equivalents were $11.9M as of March 31, 2026 and $20.4M as of May 8, 2026, including $7.8M in restricted cash for the OPKO collaboration. Management expects current funds to support operations through the first quarter of 2027 as it advances oral peptide programs EB613, EB612, and EB618.
Entera Bio Ltd. entered a Securities Purchase Agreement with funds affiliated with BVF Partners for a private placement of 7,827,789 units at $1.2775 per Unit, for aggregate proceeds of approximately $10.0. Each Unit includes one ordinary share (or a Pre-Funded Warrant) and one warrant to purchase one and a half ordinary shares.
The Pre-Funded Warrants are immediately exercisable at NIS 0.0000769 per share with no expiration, subject to a 4.99% beneficial ownership cap that may be increased up to 19.99%. The Ordinary Share Warrants have a $1.24 exercise price, become exercisable six months after closing, and expire five years after issuance.
If all Ordinary Share Warrants are exercised for cash, Entera Bio expects to receive additional proceeds of approximately $14.5 million. The company plans to use net proceeds from the private placement to support initiation of its phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.
Entera Bio is a clinical-stage company developing first-in-class oral peptide and protein replacement therapies using its N-Tab® platform. Its lead candidate, EB613, an oral teriparatide tablet for postmenopausal osteoporosis, has completed Phase 2 and is moving toward a planned ~750-patient multinational Phase 3 trial using total hip bone mineral density as the primary endpoint under a 505(b)(2) pathway referencing Forteo®.
The company is also advancing EB612, an oral long-acting PTH(1-34) tablet for hypoparathyroidism, and EB618, an oral GLP-1/Glucagon dual agonist for obesity and metabolic disorders, both in collaboration with OPKO, as well as an oral GLP-2 program for short bowel syndrome. Entera reports a broad global patent estate covering EB613, EB612, GLP-1/Glucagon, GLP-2 and the N-Tab® platform, with nominal patent terms extending into the 2030s and 2040s. The company notes Israeli Innovation Authority grants with associated royalty obligations and discloses that, as of June 30, 2025, non-affiliate voting stock held a market value of approximately $84.6 million, with 46,622,239 ordinary shares outstanding as of March 23, 2026.
Entera Bio reported a full-year 2025 net loss of $11.4 million, or $0.25 per share, compared with a $9.5 million loss in 2024, as it increased investment in its oral peptide pipeline.
Cash and cash equivalents totaled $14.9 million as of December 31, 2025, including $7.8 million in restricted cash designated for the OPKO collaboration, and are expected to fund operations through the middle of the third quarter of 2026.
The company advanced three key programs: EB613, an oral anabolic osteoporosis tablet with Phase 3 protocol submitted to the FDA after a Type A endpoint alignment meeting in July 2025; EB612, a long-acting oral PTH replacement for hypoparathyroidism with final variants selected and pre-IND work underway toward a planned late-2026 IND filing with OPKO; and EB618, an oral dual GLP-1/glucagon tablet for metabolic disease with PK/PD validation complete and an IND planned based on OPKO Phase 1 data.
Entera Bio Ltd. director Germano Geno J reported an open-market purchase of 20,000 Ordinary Shares on March 9, 2026 at a price of 1.30 per share. After this transaction, he directly owns 40,000 Ordinary Shares, doubling his reported direct stake.
Entera Bio Ltd. director Sean Ellis reported an open-market purchase of 10,000 ordinary shares of Entera Bio on March 5, 2026. The weighted average purchase price was $1.23 per share, with individual trades executed between $1.2287 and $1.245. Following this transaction, Ellis directly owns 188,098 ordinary shares of Entera Bio.
Entera Bio Ltd. filed a current report describing a key clinical milestone for its lead osteoporosis candidate EB613. The company has submitted to the FDA a streamlined Phase 3 protocol, statistical analysis plan, and open-label extension synopsis under its existing IND for oral teriparatide.
The planned registrational Phase 3 study will enroll 750 postmenopausal women with osteoporosis and use percentage change in total hip bone mineral density at 12 months, rather than 24 months, as the primary endpoint. Entera plans to advance a new single-tablet, once-daily formulation of EB613 directly into this trial and anticipates initiating the study in late 2026, with topline results expected in the second half of 2028.
Entera Bio Ltd. director Steven D. Rubin reported an open-market purchase of 5,000 ordinary shares at $1.49 per share on February 12, 2026. Following this transaction, he directly beneficially owns 15,000 ordinary shares of Entera Bio.
Entera Bio Ltd. director Haya Taitel reported buying 7,500 ordinary shares on February 10, 2026. The Form 4 shows a purchase at a weighted average price of $1.48 per share, executed through multiple trades between $1.47 and $1.4799, with the holding reported as direct ownership.
Entera Bio Ltd. director transaction: Director Germano J. Geno reported buying 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026. The shares, each with a par value of NIS 0.0000769, were purchased in a direct ownership transaction at a price of $1.49 per share.